AbbVie closes $200M Nimble Therapeutics acquisition
299BUSD
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US00287Y1091
CUSIP
00287Y109
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
59.47
PEG Ratio
0.40
Book Value
3.41
Dividend Share
6.2
Dividend Yield
3.84%
Earnings Share
2.87
Wall Street Target Price
199.9696
EPS Estimate Current Year
10.7082
EPS Estimate Next Year
12.1852
EPS Estimate Current Quarter
2.91
EPS Estimate Next Quarter
2.95
Most Recent Quarter
-
Revenue TTM
55,532,998,656
Gross Profit TTM
39,059,001,344
EBITDA
25,629,999,104
Profit Margin
9.22%
Return On Assets TTM
7.72%
Return On Equity TTM
56.41%
Revenue Per Share TTM
31.397
Qtly Revenue Growth YOY
3.80%
Diluted Eps TTM
2.87
Qtly Earnings Growth YOY
-12.30%
Trailing PE
59.47
Forward PE
14
Price Sales TTM
5.431
Price Book MRQ
49.9996
Enterprise Value Revenue
6
Enterprise Value EBITDA
20
88.08
8.62%787.25
2.72%69.33
1.04%38.09
0.63%146.85
0.15%317.34
0.00%135.54
-1.83%99.23
-0.64%96.06
-0.60%304.04
-0.08%See which Billionaires own this investment
AbbVie closes $200M Nimble Therapeutics acquisition
STARTS NOW! Rebel Edge 🏴☠️1pm line up: U.S. crude oil prices are dropping due to weak demand from China and expected higher U.S. production after the election. WTI is notably lower, part of a wider commodity slump. Stocks $TSLA $COIN $ABBV $HOOD Sports Detroit's kicker makes 58… https://t.co/mZXNAn84q8 https://t.co/HBCDrov0gz
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
AbbVie to buy Aliada Therapeutics for $1.4B in cash
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease